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Abstract Cisplatin (CDDP) nephrotoxicity is one of the
most common side effects in cancer treatment, causing the
disruption of chemotherapy. In this study, we analyzed the
influence of nongenetic factors on CDDP-induced
nephrotoxiciy using the data from 182 CDDP-treated and
52 carboplatin (CBP)-treated patients. Themean change of
eGFR (100 % to baseline) in CDDP-treated patients was
−9.2 %, which was significantly lower than that in the
population with CBP therapy. By using the chi-squared
test and multivariate logistic regression analysis, age
(≥50 years) is found associated with CDDP-induced neph-
rotoxicity, with odds ratio (OR) of 9.167 and 11.771,
respectively. Three- and 18-month-old mice were
employed to study the age-dependent susceptibility of
CDDP-induced nephrotoxicity. Biochemical parameters,
histopathogical examination, and mRNA biomarkers indi-
cated that old mice were subjected to more severe kidney
injury. In addition, old mice accumulated more CDDP in
kidney than young mice, and the protein level of CDDP
efflux transporter, MATE1, in aged mice kidney was 35%
of that in young mice. Moreover, inflammatory receptor
TLR4 was higher in the kidney of old mice, indicating the
alteration of inflammatory signaling in old mice. After
CDDP administration, the induced alterations of TNF-α,
ICAM-1, and TLR4 were more extensive in old mice. To
summarize, aging increased the susceptibility of CDDP-
induced renal function decline or nephrotoxicity.
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Introduction
Cisplatin (CDDP) is a long used inorganic metal drug,
with a wide usage in the treatment of solid tumors such
as head and neck, lung, testis, ovarian, and bladder
cancers. Althoughmany other platinum antitumor agen-
cies with reduced toxicity have been developed, CDDP
is still favored in antitumor treatment given its defined
therapeutic effect.
The most common side effects of cisplatin include
ototoxicity, gastrointestinal and hematologic toxicities,
acute kidney injury, and chronic kidney function decline
(Evans et al. 1981; Loehrer and Einhorn 1984). Due to
the high prevalence rate and severity of nephrotoxicity,
the duration of CDDP chemotherapy is often
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terminated, affecting the prognosis. In the past decade,
the investigation of CDDP-induced nephrotoxicity
became the focus of acute kidney injury (AKI) study.
The mechanism of cisplatin-induced nephrotoxicity is
complicated, involving apoptosis, inflammation, mito-
chondria dysfunction, ROS, DNA damage, autophagy
and the specific accumulation in S3 segment of renal
tubules (Pabla and Dong 2008; Ozkok and Edelstein
2014). Recently, many studies have highlighted the role
of CDDP accumulation in CDDP-induced nephrotoxi-
city. It was demonstrated that CDDP was transported
into proximal tubular cells through the basal transporters
OCT2 (Franke et al. 2010) and CTR1 (Pabla et al. 2009)
from plasma, and excreted into urine via MRP2 (Wen
et al. 2014) and MATE1 (Nakamura et al. 2010) located
at the apical membrane. Recently, Masayuki et al. (Oda
et al. 2014) reported that the rhythmic oscillations of
renal OCT2 protein levels by circadian clock was a
possible mechanism of dosing time-dependent changes
in CDDP-induced nephrotoxicity. In addition, drug in-
teraction on and the genetic variations of CDDP trans-
porters were also found in a relationship to CDDP-
induced nephrotoxicity (Tanihara et al. 2009; Iwata
et al. 2012; Zhang and Zhou 2012; Sprowl et al. 2013).
A retrospective analysis fromAmerican head and neck
cancer patients demonstrated that elder patients were
more susceptible to CDDP-induced toxicities including
renal toxicity (Argiris et al. 2004). In support of this, a
recent study in Indonesia reported that age ≥50 years was
correlated to CDDP-induced renal function decline (odd
ratio=3.4) (Prasaja et al. 2015). However, there are also
studies against this positive relationship between age and
CDDP nephrotoxicity (Cubillo et al. 2001; Moscetti et al.
2005). In the present study, we analyzed the data from
Chinese lung cancer patients with CDDP-based chemo-
therapy and further compared the CDDP-induced neph-
rotoxicity in young mice with that in old mice.
Materials and methods
Chemicals
CDDP was purchased from Sigma-Aldrich (St. Louis,
MO, USA) and dissolved in 0.9 % saline. MRP2 (rabbit
polyclonal anit-mouse) and CTR1 (rabbit polyclonal
anit-mouse) were purchased from Abcam (Cambridge,
MA, USA), and OCT1, OCT2, TNF-α, and IL-1βwere
purchased from Proteintech (Wuhan, Hubei, China).
MATE1 and Nrf2 were purchased from Santa Cruz
Biotechnology (Dallas, TX, USA). ICAM-1 and TLR4
were purchased from Bioworld (St. Louis Park, MN,
USA). All secondary antibodies were obtained from
Santa Cruz Biotechnology.
Patients
We retrospectively reviewed lung cancer patients who
were admitted to Hunan Cancer Hospital, Central South
University, from 2011 to 2015. Patients were treated
with CDDP and given routine nephrotoxicity prevention
procedure of hydration or treated with CBP. Creatinine
clearance is an estimated glomerular filtration rate
(eGFR) calculated by the Cockroft-Gault (CG) equa-
tion. Only the first chemotherapy cycle was evaluated.
Patient’s nephrotoxicity was defined as renal function
decline characterized by the change of eGFR to baseline
lower than −30 %, which was the approximately the
minimum value in patients with CBP-based therapy.
Patients without the data of serum creatinine before
CDDP infusion and after CDDP infusion were exclud-
ed. Moreover, patients who administrated other poten-
tial other nephrotoxic drugs (anti-HIVs, NSAIDs,
vancomycin, aminoglycoside antibiotics) and pretreated
with platinum-based chemotherapy were excluded.
Variables studied as risk factors of renal function decline
were age (<50 and ≥50 years old), gender, BMI, and
comorbidities (hypertension and diabetes mellitus).
Animal treatment
C57BL/6 mice (male, 3- and 18-month-old) were pur-
chased from Hunan SJA Laboratory Animal
Corporation and maintained in accordance with the
guidelines for the care and use of laboratory animals as
issued by the Center for Scientific Study with animal
models of Central South University. The mice were
acclimatized under normal environmental conditions
and allowed free access to standard chow and tap water
for 1 week before experimentation.
Mice of both age groups (18 per group) were ran-
domized to receive either saline intraperitoneal injection
or CDDP intraperitoneal injection (15 mg/kg). All mice
were weighed before CDDP administration, and ani-
mals were euthanized 72 h post-CDDP injection, after
which the abdominal cavity was opened for inspection
of the kidneys. Part of the kidney was incised and fixed
in formalin for histological examination, while the
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resulting parts were kept in liquid nitrogen for the ex-
traction of messenger RNA (mRNA) and protein, as
well as for CDDP quantification. At the same time, a
blood sample was obtained by orbital puncture and
analyzed for urea, creatinine, and other parameters.
This study was approved by the Independent Ethics
Committee Institute of Clinical Pharmacology, Central
South University. Five-micron paraffin-embedded kid-
ney sections were stained with H&E and were examined
for histopathological changes by a board-certified pa-
thologist from Xiangya Hospital. Neutrophils were
counted from five to six mice per group in three non-
o v e r l a p p i n g h i g h - p ow e r f i e l d s ( H P F ) .
Immunofluorescence analysis was performed for Nrf2.
Sections were washed and incubated with goat anti-
rabbit IgG (Boster, Wuhan, China).
Blood biochemistry
Blood creatinine (Cr), blood urea nitrogen (BUN), and
aminotransferase (ALT) were determined on a fully
automated clinical chemistry analyzer, LWC400
(Shenzhen, China).
CDDP detection
Plamas and kidney samples from mice 4 to 72 h after
injection were analyzed for CDDP concentration. The
biosamples were weighed or quantified before dissolv-
ing in the 8 mL 70 % nitric acid and 2 mL 30 %
hydrogen peroxide. The mix was then digested on elec-
tric heating panel for overnight and diluted to 5 mL. The
resulting lysate was centrifuged at 12,000 rpm for
10 min, and 50 μL supernatant was diluted by adding
450 μL internal control solution of mass spectrometry
analysis containing 10 ng/mL iridium and 0.1 % Triton
X-100. The platinum content was measured by induc-
tively coupled plasma mass spectrometry in the
Analytical Center of Kemen Corporation (Changsha,
Hunan, China).
Reverse transcription and real-time qPCR
Total RNA was isolated from the renal cortex tissues
using TRIzol and phenol-chloroform method. The total
RNA (1 μg) was reversely transcribed using a high
capability reverse transcription kit with DNA erase
(Takara) and then diluted ten times. Five microliters
was then used as the template for real-time PCR. The
real-time qPCR was formed in duplicate using specific
primers of the targeted genes (Supplementary Table 1;
PrimerBank of Harvard Medical School), 5 μL cDNA
templates, and 10 μL two-step SYBR green I mixture
(Takara). The real-time qPCR condition was as follows:
an initial 5-min preincubation step at 95 °C, followed by
40 cycles of two-step at 94 °C for 30 s and 60 °C for
60 s. Real-time PCR was performed on Roche 480.
Relative changes in gene expression were calculated as
fold changes using the comparative ΔΔCt method
(where Ct is threshold cycle). Mice glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeper was
used as the housekeeping gene for normalizing tran-
script levels.
Western blotting
Renal tissue lysate was prepared by homogenation in
lysis buffer (50 mM Tris, pH 7.5, 150 mM sodium
chloride, 1 mM phenyl-methylsulfonyl fluoride, 1 mM
sodium orthovanadate, 1 % Nonidet P-40, 50 mM sodi-
um fluoride, 10 mg/mL proteinase inhibitors mixture,
10 % glycerol) at 4 °C, followed by the centrifugation at
14,000 rcf at 4 °C for 10 min. Protein concentration was
measured by the Bradford assay, using bovine serum
albumin as standard. Proteins (25 μg/lane) were sepa-
rated by SDS-PAGE and then transferred to
polyvinylidene difluoride membranes (Millipore,
Billerica, MA). Nonspecific binding was blocked by
preincubation of the PVDF membrane in Tris-buffered
saline containing 0.1 % Tween 20 (TBS-T) and 5 %
skimmed milk for 1 h. The PVDF was then incubated
overnight at 4 °C with primary antibodies. After being
washed, blots were then incubated with HRP-labeled
secondary antibody and washed before bands were re-
vealed using the BioRad imaging system. Band densi-
ties were determined using the β-actin or housekeeping
proteins, and quantitation was determined using Image-
Pro Plus software.
Statistical analysis
Statistical analysis was conducted by Statistical
Products Social Science (SPSS) 19 for Windows.
Experimental values are expressed as mean±SEM.
Comparison of mean values between groups was per-
formed by unpaired t test or one-way analysis of vari-
ance (one-way ANOVA) followed by post hoc Tukey
test. P<0.05, P<0.01, and P<0.001 were considered to
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be significant. Chi-squared test was used to analyze the
relationship between risk factors (age, gender, BMI, and
comorbidities) and nephrotoxicity incidence after the
first chemotherapy cycle. Finally, multivariate analysis
with logistic regression test was used to analyze the risk
factors for nephrotoxicity in patients taking CDDP.
Results
Clinical observation
In this study, a total of 240 subjects of lung cancer
patients were recruited in accordance with the criteria
of subject recruitment. Patients who received CDDP
treatment were 182 people, while the patients with
CBP chemotherapy were 58. Table 1 describes the gen-
eral and clinical characteristics of these subjects. Three
to four days after platinum dosing, eGFR decreased
significantly in patients receiving CDDP injection com-
pared to CBP injection (Fig. 1a). With respective to the
change of eGFR, it decreased significantly in CDDP-
treated patients with the age ≥50 than <50 years
(Fig. 1b), whereas the change of eGFR was similar
between the two age groups of CBP-treated population
(Fig. 1c). Table 2 shows the factors affecting CDDP-
induced decline of renal function by using chi-squared
test. Among these factors, only age (p=0.011, OR=
9.167, 95 % CI=1.192–70.475) had a significant
relationship with renal function decline after the first
cycle of CDDP chemotherapy. Multivariate analysis
using logistic regression showed that age (p=0.020,
OR=11.771, 95 % CI=1.470–94.266) had a significant
association with the decline of renal function, while
Table 1 Patient clinicopathologic characteristics and chemother-
apy regimens
Cisplatin Carboplatin
Patients number 182 52
Age (mean±SD, years) 54.18±0.63 56.52±1.27
Sex (female/male) 33/148 19/32










Fig. 1 Change of eGFR in the patients with CDDP- and CBP-
based therapies. a Change of eGFR (100 % of baseline) in the
patients (n=182) treated with CDDP after the first cycle of
chemotherapy was significantly below that in carboplatin-treated
patients (n=58). b Among the patients with CDDP-based therapy,
change of eGFR decreased significantly in patients with the age
≥50 than <50 years. c In patients with CBP-based therapy, there
was no change in the alteration of eGFR between the age ≥50 and
<50 years
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other factors still had no statistically significant relation-
ship with renal function decline.
Body weight change and biochemical parameters
During the experiment, two mice in the aged group died
2 days after the CDDP injection. CDDP decreased body
weight by 15 and 16 % in aged and young groups,
respectively. There was no remarkable change in body
weight of control mice at either age (Table 3). Results of
blood biochemistry for nephrotoxicity and hepatotoxic-
ity are shown in Table 3. CDDP treatment significantly
increased the levels of BUN, Cr, and ALT in old aged
group, but not in young group.
Histopathogical examination
There was no apparent renal histopathology change in
control mice of both ages. However, following treat-
ment with CDDP, remarkable proximal tubule cell ne-
crosis, proximal tubule degeneration, and hyaline casts
were observed (Fig. 2a, b). Although the glomerulus did
not appear to be affected by CDDP treatment in both age
groups, the proximal tubule damages were more exten-
sive in old age group compared with the young. In
addition, more neutrophil infiltration was found in old
mice kidney than the young after CDDP injection
(Fig. 2c).
mRNA biomarkers of CDDP-induced nephrotoxicity
mRNA molecules related to kidney injury were exam-
ined in the mice receiving CDDP in both age groups.
The transcript levels of the Kim-1, Lcn2, and HO-1,
which are the indicators of AKI, were remarkably ele-
vated by CDDP treatment (Fig. 3).
Antioxidant pathway related to CDDP-induced
nephrotoxicity
The transcriptional expression of antioxidation genes
HO-1, GCLC, and NQO-1 that were overexpressed by
CDDP treatment can scavenge the excessive reactive
oxidative species induced by CDDP. It was also reported
that HO-1, GCLC, and NQO-1 were regulated by Nrf2/
Keap1 signals and can be the indicators of CDDP-
induced nephrotoxicity (Aleksunes et al. 2010). The
detoxification products of CDDP can be extruded via
MRP2which was upregulated byNrf2. Thus, we further
detected the mRNA levels of these molecules (Figs. 3
and 4a). All these genes were transcriptionally upregu-
lated by CDDP treatment. However, only CDDP-
induced upregulation of HO-1 mRNA was more






P value OR (95 % CI)
n % n %
Gender
Female 5 15.2 28 84.8 0.328 1.722 (0.574, 5.169)
Male 14 9.4 135 90.6
Age
≥50 18 14.3 108 85.7 0.011 9.167 (1.192, 70.475)
<50 1 1.8 55 98.2
BMI
≥25 1 3.2 30 96.8 0.149 0.246 (0.032, 1.918)
<25 18 11.9 133 88.1
Diabetes
Yes 1 16.7 5 83.3 0.612 1.756 (0.194, 15.871)
No 18 10.2 158 89.8
Hypertension
Yes 2 16.7 10 83.3 0.465 1.800 (0.364, 8.904)
No 17 10 153 90
Table 3 Change of body weight and serum plasma biochemical indicators after CDDP injection in mice (n=7–9)
Age Treatment BW change (%) BUN (mmol/L) Cr (μmol/L) ALT (U/L)
3-month old NS −0.2±0.83 9.94±0.74 36.1±2.54 32.8±2.57
CDDP −16.56±0.44* 18.64±2.94 44.55±3.01 37±3.85
18-month old NS −0.16±0.53 15.03±1.73 53.73±3.18 42.5±3.99
CDDP −15.8±1.49* 47.16±2.91*,** 168.0±36.1*,** 68.3±6.96*,**
*P<0.05, compared with NS control; **P<0.05, compared with 3-month-old group of CDDP treatment
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profound in old mice kidney than that in young mice.
There was no difference on the increasing of GCLC,
NQO-1, and MRP2 by CDDP treatment in both age
groups. Furthermore, Western blot and immunofluores-
cence (IF) showed that the nuclear translocations of Nrf2
in old mice were more than that in young mice (Fig. 4).
CDDP concentration
Renal specific accumulation of CDDP is tightly related to
the severity of its nephrotoxicity. Using ICP-MS detection
method, it showed that renal concentrations of CDDP in
old mice were significantly higher than that in young mice
at the time of 24, 48, and 72 h post-CDDP injection
(Fig. 5a). Additionally, the old mice had a 30 % increase
in the area under the curve over the young group. At 4 and
24 h post-CDDP injection, the plasma concentrations of
CDDPwere higher in old group than those in young group
(Fig. 5b), indicating a lower plasma CDDP clearance of
old mice. However, the plasma concentrations were com-
parable between the two groups at the time of 48 and 72 h
post-CDDP injection.
Kidney uptake and efflux transporters
Given the fact that old mice accumulated more CDDP in
their kidneys, it was easily to conceive that the age-
dependent change of transporters might have an influ-
ence on renal tubule-mediated uptake and excretion of
CDDP. Thus, we quantified both the mRNA and protein
levels of CDDP uptake transporters OCT1, OCT2, and
CTR1, as well as the efflux transporters, MATE1 and
MRP2 (Fig. 6). Among these transporters, only OCT2
mRNA levels were significantly downregulated in old
mice kidney, whereas its protein levels kept unchanged.
There was nearly 2-fold decrease in MATE1 protein
levels in old mice kidney compared with young mice
kidney, whereas the renal MATE1 mRNA levels of the
two age groups were basically the same.
Changes of inflammation related to CDDP-related
kidney injury
Inflammatory response is an important mechanism lead-
ing to CDDP-related kidney injury. TLR4, the most
Fig. 2 Histopathologic injury in
young and old mice treated with
CDDP. Three- and 18-month-old
mice were treated with vehicle or
15 mg/kg of i.p. CDDP, and
kidneys were collected 72 h after
CDDP injection. Samples were
fixed in formalin before routine
processing and paraffin
embedding. a Five-micron
sections of kidneys were stained
with hematoxylin and eosin and
were examined by light
microscopy for the presence and
severity of renal cast formation
(asterisk) and proximal tubule
degeneration (number sign)
(×400 magnification). b
Histological damage grades were
scored by two pathologists based
on the percentage of tubule
degeneration and necrosis (0=no
injury, 1=<10 %, 2=10–25 %,
3=26–40 %, 4=40–50 %,
5=>50 %). c The number of
neutrophils were quantified in
hematoxylin-and-eosin-stained




112 Page 6 of 13 AGE (2015) 37: 112
thoroughly studied member of the TLR family, can
initialize the process of inflammation (e.g., the upregu-
lation of TNF-α). Figure 7 shows that the protein levels
of TLR4 were significantly increased in the kidneys of
old mice, while there was a nonsignificant increasing
trend in its mRNA levels. After CDDP injection, TNF-α
levels were increased, TLR4 and ICAM-1 were de-
creased, and IL-1β was not changed in both age groups
(Fig. 8). Moreover, CDDP-induced decline of TLR4 and
ICAM-1 and augment of TNF-α were more profound in
the old group than in the young (Fig. 8). Interestingly, all
the renal mRNA levels of TLR4, ICAM-1, TNF-α, and
IL-1β were augmented after CDDP administration, even
with a higher increasing trend in old age group than
young group (data are shown in Supplementary Fig. 1).
Discussion
In the present study, we investigated the association
between nongenetic factors and CDDP-induced renal
clearance decline, and the difference of CDDP-induced
nephrotoxicity in the two age groups of C57BL/6J mice.
By the retrospective analysis of the renal function data
from the patients, we found that the old age was an
independent risk factor to the decline of renal function.
In the mice model with the two age groups, CDDP-
induced nephrotoxicity was also significantly more se-
vere in the old mice than the young mice.
Although the BUN and Cr of the young mice after
CDDP injection did not significantly increase, there
were some abnormalities in histological examination
of the renal proximal tubules. In the guideline of cancer
therapy, CTCAE4.0, a 1.5-fold increase of serum Cr is
considerate as grade 1 AKI. However, it is commonly
regarded that Cr will have an obvious increase only
when the nephrons are largely damaged. Recent studies
of renal toxins revealed that urine Kim1, NGAL, and
other molecules outperform the traditional biomarkers
of nephrotoxicity (Mishra et al. 2004; Gautier et al.
2010; Vizeacoumar et al. 2010). In our previous study
(Li et al. 2013), the mRNA levels of Kim1 and Lcn2
were remarkably increased, despite that the BUN and Cr
did not have the equivalent elevating trends. From the
data of 182 patients with CDDP chemotherapy, only one
patient had the 1.5-fold increase in serum Cr after
CDDP injection. Nonetheless, most of these patients
have a slighter Cr increase than the patients with CBP
chemotherapy. Although urine Kim1 and NGAL were
the highly approved biomarkers for the indication of
nephrotoxicity in animal trials, they are currently not
applied clinically. It is, therefore, extremely pivotal to
validate these renal biomarkers in human clinical trials.
In the association study of the nongenetic factors and
CDDP nephrotoxicity, the selection of the endpoint is of
great importance. In a recent study of Indonesian cancer
patients, Yenny et al. (Prasaja et al. 2015) chose renal
function decline characterized by creatinine clearance
<60ml/min as the nephrotoxicity criterion. It is a kind of
abitrary because the creatinine clearance after CDDP
Fig. 3 mRNA biomarkers of CDDP-induced nephrotoxicity. The
mRNA levels of Kim1, Lcn2, and HO-1 were measured by RT-
qPCR. n=6 to 9. *P<0.05, **P<0.01, ***P<0.001
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injection is also tightly related to the baseline value of
creatinine clearance, which was not adjusted in this
study. According to other studies (Tzvetkov et al.
2011; Sprowl et al. 2012), we chose the change ratio
of eGFR as the indicator of renal function. To determi-
nate the boundary of nephrotoxicity, we abitrarily
Fig. 4 The change of antioxidant pathway related to CDDP-
induced nephrotoxicity. a The mRNA levels of GCLC, NQO-1,
and MRP2 in mice kidney from vehicle or CDDP-treated mice
(n=6 to 9). b The protein level of Nrf2 in the nucleus and
cytoplasm from renal kidney cells. c Immunofluorescent staining
of Nrf2 in kidney sections of young and old mice treated with
cisplatin (blue, DAPI staining; red, Nrf2; white arrow, nucleus
staining of Nrf2). *P<0.05, **P<0.01, ***P<0.001
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employed the change of eGFR to baseline lower than
−30 %, which seldom happened in patients with CBP-
based chemotherapy. To eliminate the inference from
the multiple cycles of CDDP chemotherapy, only
the data of the first CDDP chemotherapy was
included. The finding that old age was a risk
factor of CDDP nephrotoxicity was further sup-
ported by the experiments in aged mice.
Fig. 5 CDDP concentrations in the kidney of 3- or 18-month-old
mice treated with CDDP. The concentrations were quantified by
inductively coupled plasma mass spectrometry in the kidneys (a)
and plasma (b) of young and old mice treated with 15mg/kg of i.p.
cisplatin. n=4 to 6. *P<0.05, **P<0.01
Fig. 6 Change of cisplatin transporters in the kidney of 3- or 18-
month-old mice. a The mRNA levels of OCT1, OCT2, CTR1,
MATE1, and MRP2 were measured (n=7 to 9). b Expression
levels of OCT1, OCT2, CTR1, MATE1, and MRP2 were
measured by Western blot analysis using their respective antibod-
ies. c The relative ratio of OCT1, OCT2, CTR1, MATE1, and
MRP2 toβ-actin was determined by densitometry and are reported
as mean±SEM (n=4). *P<0.05, **P<0.01, ***P<0.001
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Fig. 7 Expression levels of
TLR4 in the kidney of young and
old mice. The mRNA levels (a)
(n=5–8) and protein levels (b) of
TLR4 were measured. c
Densitometric analysis of TLR4
to β-actin ratio on Western blot
(n=4). **P<0.01
Fig. 8 Change of inflammatory factors in the kidney of 3- or 18-
month-old mice treated with cisplatin. Protein expression levels of
ICAM-1, TNF-α, TLR4, and IL-1β in young (a) and old (b) mice
treated withNS and CDDPweremeasured. Densitometric analysis
of the ratio of ICAM-1, TNF-α, TLR4, and IL-1β to β-actin in
young (c) and old (d) mice groups are shown. e The change ratios
of ICAM-1, TNF-α, TLR4, and IL-1β protein in CDDP-treated
mice to control mice in old mice group were compared with that in
young group. n=4. *P<0.05, **P<0.01, ***P<0.001
112 Page 10 of 13 AGE (2015) 37: 112
In a study from The Jackson Laboratory, the old age
of mice was regarded as a period when senescent chang-
es can be detected in almost all biomarkers in all animals
(The Jackson Laboratory 2011). For C57BL/6J mice,
the lower limit of old is 18 months, whereas 3 months
old was thought to be the mature adult. Thus, in the
design of experiment, we chose 3- and 18-month-old
mice as the young and old age groups, respectively.
After CDDP injection (15 mg/kg), both the plasma
BUN and Cr concentration in the old group had a 2-
fold increase of that in control group, indicating a severe
nephrotoxicity. Additionally, the mRNA biomarkers of
kidney injury (Kim1, Lcn2, HO-1) and the results of
histological analysis all supported that aged mice was
more susceptible to CDDP-induced nephrotoxicity.
Besides, two mice in old mice group died in the third
day after CDDP injection, which could be caused by the
severe nephrotoxicity.
There are two kinds of CDDP in plasma, the bound
and unbound CDDP. Unbound CDDP is largely elimi-
nated through renal filtration within 4 h post-injection
(Vermorken et al. 1984; Vermorken et al. 1986).
Moreover, CDDP is specifically accumulated in kidney,
through the uptake transporters OCT1, OCT2, and
CTR1, and excreted into urine via MATE1 and
MRP2 at the apical membrane of proximal tubular cells.
Our study demonstrated a higher CDDP accumulation
in the kidney of old mice, in accordance with their
severe nephrotoxicity. The 65 % decrease of MATE1
in old mice kidney can limit the extrusion of CDDP,
causing more CDDP renal accumulation and severe
nephrotoxicity. We also found that the mRNA of
OCT2, but not the protein level, was downregulated in
aged mice. However, in a study of aged rats, both the
mRNA and protein levels were found decreased in old
age group (Ren et al. 2014). It would be interesting to
investigate the mechanism concerning the change of
these transporters among different species. Besides, it
was reported that the glomerular filtration and renal
blood flow rates declined in a linear fashion after the
age of 30 (Anderson and Brenner 1986; Muhlberg and
Platt 1999). Therefore, the renal elimination of
CDDP decreased in old mice, which resulted in
high plasma CDDP concentration especially from
4 to 24 h after CDDP dosing. In this regard, the
high plasma CDDP concentration could force more
drugs into the kidney tubular cells via the basal
membrane. In summary, both the downregulation
of MATE1 and the decrease of CDDP filtration
can contribute to the increased renal accumulation
of CDDP.
The signaling of Toll-like receptors (TLRs) are
widely expressed in leukocytes and kidney epithe-
lial cells, regulating innate and adaptive immune
responses, which is an important pathway leading
to AKI (Anders et al. 2004). With respect to
CDDP-induced nephrotoxicity, the knockout of
TLR4 significantly decreased CDDP-induced in-
flammatory cytokines and its severity of nephro-
toxicity (Zhang et al. 2008). In our study, we
found that old mice expressed more TLR4 in
kidney and also had a higher increase of TNF-α
after CDDP dosing. Although higher CDDP accu-
mulation in the kidney of old mice can produce
more TNF-α, it cannot overlook the influence of
age on inflammatory response. Mounting data have
evidenced the age-related alterations in the inflam-
matory response to dermal injury (Swift et al.
2001), pneumonia (van Vught et al. 2014), brain
trauma (Timaru-Kast et al. 2012), fibrosis
(Mahrouf-Yorgov et al. 2011; Wolf et al. 2012),
acute coronary syndrome (Badran et al. 2009), etc.
Therefore, the upregulation of TLR4 that initiate
the inflammatory response is partially responsible
for the susceptibility of CDDP-induced nephrotoxicity in
old mice. It was interesting that both the TLR4 and
ICAM-1 were downregulated in renal tissues, but not
IL-1β. It has been demonstrated that renal TLR4 protein
shed into the urine after the stimulation of toxins, whereas
the mRNA level were still increasing (Zager et al. 2007).
Our results were in support of this finding. Moreover, we
showed that the extent of TLR4 decreasing is related to the
severity of CDDP nephrotoxicity. However, why this
shedding happens and what is the outcome of TLR4
shedding are still not fully understood. It is also unclear
whether the decrease of ICAM-1 and the unchanged IL-1β
levels are caused by their secretion into plasma or shedding
into urine.
Nrf2 is a cytoprotective factor in various pathological
processes including CDDP-induced AKI. The expres-
sion of HO-1, Gclc, NQO-1, and MRP2, via activation
of Nrf2, has the capacity to quench free radicals and
electrophiles caused by CDDP. In addition, the levels of
these molecules are thought to parallel to the severity of
CDDP nephrotoxicity. Several studies have reported
that aging is associated with diminished antioxidant
capacity and increased accumulation of reactive oxygen
and nitrogen species. Recently, Sellamuthu et al.
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(Gounder et al. 2012) demonstrated that the inducible
antioxidant pathways of Nrf2 were impaired in the aging
heart of mice, as evidenced by the decreased nuclear
translocation of Nrf2, ARE-binding activity of nuclear
Nrf2, and scavenging of reactive oxygen species. In our
study, the levels of GCLC, NQO-1, and MRP2 were
comparable in both age kidneys, whereas the CDDP
accumulation and the nephrotoxicity severity were
higher in old group. Thus, it is conceived that in aging
kidneys, the antioxidant pathways of Nrf2 is also im-
paired, causing the relative lower level of GCLC, NQO-
1, and MRP2. Western blot and IF were in support that
age weakened the signaling of Nrf2 in mice kidney.
Inconsistently, the induced levels of HO-1 were higher
in aged mice than those in young mice. It is further
important to reveal the protein levels of these antioxi-
dant molecules induced by Nrf2 and the mechanism
why age blunts Nrf2 activity.
Also, these are some other shortages in our study. In
the animal experiment, the urine samples are not col-
lected. Thus, we did not analyze the urinary nephrotox-
icity biomarkers and the urine CDDP clearance, which
can make the study more convincing. Moreover, only
the retrospective clinical data was obtained and there-
fore, the gene polymorphisms of the patients are not
available. It is our future work to investigate the factors
of age and gene polymorphisms on the pharmacokinet-
ics of CDDP in patients.
Conclusion
The finding from this study demonstrated that old age
was a risk factor to CDDP-induced renal clearance
decline or nephrotoxicity. The results from the animal
experiments showed that old mice accumulated more
CDDP in kidney than young mice, which was highly
related to the age-dependent susceptibility to CDDP-
induced nephrotoxicity. Moreover, the altered inflam-
matory response and antioxidant signaling in aged kid-
neys partially contributed to the age-dependant suscep-
tibility of the renal injury.
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